FDA Cybersecurity Enforcement in Medical Devices: What the Latest Trends Mean for Your Regulatory Strategy

FDA Cybersecurity Enforcement Is No Longer a Future Risk — It Is a Present Reality

For years, medical device cybersecurity occupied an uncomfortable middle ground: widely acknowledged as critical, yet rarely a hard stop in FDA review cycles. That era is over. Since the enactment of Section 524B of the Federal Food, Drug, and Cosmetic Act — codified through the Consolidated Appropriations Act of 2023 — FDA has statutory authority to refuse to accept premarket submissions for cyber devices that fail to meet cybersecurity requirements. If you are a startup founder preparing your first 510(k), or a VP of Regulatory navigating a PMA supplement, this is the enforcement landscape you are operating in right now.

What Section 524B Actually Requires

Section 524B defines a cyber device as any device that contains software, is intended to connect to the internet, or contains any software validated, installed, or authorized by a third party. That definition is broader than most teams initially assume. Under this authority, manufacturers must now submit:

• A plan to monitor, identify, and address postmarket cybersecurity vulnerabilities in a reasonable time
• A software bill of materials (SBOM) for all commercial, open-source, and off-the-shelf software components
• Evidence that the device and related systems are designed to provide reasonable assurance of cybersecurity

FDA's enforcement mechanism is a Refuse to Accept (RTA) determination at the submission intake stage. This is not a deficiency letter you respond to after 90 days — it is a hard gate. Submissions that lack the required cybersecurity documentation will not enter substantive review. For a startup burning runway, this distinction is operationally significant.

The Guiding Framework: FDA's 2023 Cybersecurity Guidance

FDA finalized its guidance document Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions in September 2023. This guidance operationalizes Section 524B and is the authoritative roadmap for what reviewers expect to see. Key concepts manufacturers must internalize include:

• Secure Product Development Framework (SPDF): FDA expects cybersecurity to be integrated throughout the total product lifecycle (TPLC), not bolted on during submission preparation. This maps directly to 21 CFR Part 820 Quality System Regulation requirements and aligns with ISO 13485:2016 risk management obligations.
• Threat modeling and risk assessment: Submissions must include a documented threat model — typically referencing frameworks like STRIDE or MITRE ATT&CK for ICS — along with a cybersecurity risk assessment that identifies assets, threats, vulnerabilities, and residual risks.
• Labeling and customer communication: Under 21 CFR Part 801, labeling must now include relevant cybersecurity information sufficient to allow users and health systems to manage the device securely.

Postmarket Enforcement: Where FDA Is Watching Closely

Premarket scrutiny is only half the picture. FDA's postmarket cybersecurity expectations — articulated in the 2016 postmarket guidance and reinforced through subsequent communications — create ongoing obligations under your 21 CFR Part 806 corrections and removals framework and your postmarket surveillance activities under 21 CFR Part 822.

FDA has signaled through warning letters and public statements that unpatched vulnerabilities in fielded devices, inadequate vulnerability disclosure programs, and failure to coordinate with ICS-CERT or CISA when critical vulnerabilities are discovered will draw enforcement attention. The agency has also increased coordination with the HHS Health Sector Cybersecurity Coordination Center (HC3), which means threat intelligence is flowing upstream to reviewers and inspectors.

During FDA inspections under 21 CFR Part 820, investigators are now specifically examining design controls documentation (820.30) for evidence that cybersecurity was addressed during design and development — not just in the 510(k) submission. Gaps between your submission documentation and your actual design history file are a primary 483 observation trigger in this space.

Practical Steps Your Team Should Take Now

If your organization has not yet operationalized cybersecurity as a quality and regulatory function, the following actions are non-negotiable in the current enforcement climate:

• Conduct a gap assessment against FDA's 2023 premarket cybersecurity guidance before initiating your next submission
• Build SBOM generation into your software development pipeline — manual assembly at submission time is not sustainable and introduces accuracy risk
• Establish a vulnerability disclosure policy and a coordinated vulnerability disclosure (CVD) process with documented response timelines
• Review your 21 CFR Part 820 design controls SOPs to confirm cybersecurity is addressed explicitly in design inputs, design outputs, and design verification and validation activities
• Map your postmarket surveillance plan to include cybersecurity monitoring as a defined activity with assigned owners

The Bottom Line for Device Companies

FDA cybersecurity enforcement has matured from guidance-driven expectation to statutory requirement with real submission consequences. Founders and regulatory leaders who treat cybersecurity as a check-the-box activity will face RTA determinations, extended review cycles, and inspection observations that consume resources and delay market access. Those who build cybersecurity into their quality systems and regulatory strategy from the start will move faster and present a more credible regulatory package to reviewers.

At ADB Consulting & CRO Inc., Andre Butler and the team work directly with medical device startups and established manufacturers to build submission-ready cybersecurity documentation, align quality systems with current FDA expectations, and develop postmarket programs that hold up under inspection. Whether you are preparing your first 510(k) or navigating a complex PMA, we bring the regulatory expertise to get it right the first time.

Book a free discovery call today at adbccro.com and let us assess where your cybersecurity regulatory strategy stands — before FDA does.